$LNAI·8-K

Lunai Bioworks Inc. · Apr 28, 5:30 PM ET

Compare

Lunai Bioworks Inc. 8-K

Research Summary

AI-generated summary

Updated

Lunai Bioworks Postpones Special Stockholder Meeting to May 8, 2026

What Happened Lunai Bioworks, Inc. announced on April 27, 2026 that it postponed its previously scheduled Special Meeting of Stockholders from May 4, 2026 to May 8, 2026 at 9:00 a.m. Eastern Time. The meeting remains virtual-only (live webcast at www.virtualshareholdermeeting.com/LNAI2026SM). The Special Meeting will consider proposals described in the company’s Definitive Proxy Statement filed April 13, 2026 (amended April 15, 2026), including a proposed reverse stock split and an adjournment proposal. Stockholders who already submitted proxies do not need to act unless they wish to change their vote; previously submitted proxies will be voted at the postponed meeting unless properly revoked.

Key Details

  • New meeting date/time: May 8, 2026 at 9:00 a.m. ET (originally May 4, 2026). Record date for voting remains April 10, 2026.
  • Reason for postponement: Broadridge distributed proxy materials to beneficial owners on April 22, 2026, which delayed timing needed for brokers to exercise discretionary voting under NYSE Rule 452. Postponement is intended to allow applicable timing requirements to be met.
  • Proposals highlighted: Reverse Stock Split Proposal and Adjournment Proposal — the company believes these are likely to be classified as “routine” under NYSE Rule 452 (final classification is made by NYSE).
  • The company filed a supplement to the Definitive Proxy Statement and a revised Notice of Special Meeting concurrently with this 8-K and encourages shareholders to submit proxies promptly.

Why It Matters The postponement is intended to give shareholders more time to vote and to allow brokers the opportunity (where permitted) to exercise discretionary voting on routine matters, which could affect whether the company obtains a quorum and the outcome of the proposals (including the reverse stock split). The filing also notes related risks — including the possibility of further postponement, proposals failing to pass, and potential Nasdaq listing implications — and urges shareholders to review the Definitive Proxy Statement and supplemental materials before voting.

Loading document...